Clinical trials: Cardiovascular Risk Factors
Hypertension, Cardiovascular Diseases
Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risks.
- Trial name
- NCT00904371
- Where
- 36 sites in Slovenia
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Cardiac Transplant Failure, Cardiac Transplant Rejection
Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Plasma donor-derived cell-free DNA (dd-cfDNA) is measured as a % of the total plasma cfDNA in association with the measurement of AlloMap, a non-invasive gene expression test to aid in heart transplant management.
- Conditions
- Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
- Trial name
- D-OAR (NCT02178943)
- Where
- 28 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CareDx
Diabetes Mellitus, Type 2
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
This study aims to estimate the number of patients with cardiovascular disease and risk factors in patients who had been diagnosed with type 2 diabetes mellitus.
- Trial name
- PICT2RE (NCT03797885)
- Testing
- No treatment given
- Where
- 14 sites in Portugal
- Volunteers
- 730 people
- Sponsor
- Novo Nordisk A/S
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
The study was designed to assess whether 6 weeks of co-administration of ezetimibe and simvastatin is more effective than simvastatin monotherapy in allowing patients in the CHD risk strata of the NCEP III guidelines to achieve…
- Trial name
- NCT00651014
- Testing
- Ezetimibe
- Volunteers
- 82 people
- Sponsor
- Organon and Co
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Arterial Hypertension
Survey to Assess Why People Are Not Responding to Treatment in Hypertension
This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
- Trial name
- NCT01071681
- Testing
- Telmisartan (Kinzal/Pritor, BAY68-9291)
- Where
- France
- Volunteers
- 1,589 people
- Sponsor
- Bayer
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Cardiovascular Diseases
CANVAS - CANagliflozin cardioVascular Assessment Study
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE).
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Risk Factors
- Trial name
- CANVAS (NCT01032629)
- Testing
- Canagliflozin (JNJ-28431754) 100 mg, Canagliflozin (JNJ-28431754) 300 mg
- Where
- 305 sites in United States, Argentina and 23 more
- Volunteers
- 4,330 people
- Sponsor
- Janssen Research & Development, LLC
Dyslipidemias, Cardiovascular Risk Factor
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Clinical Trial Phase III, experimental, simple blind, randomized with two treatment groups, multicentric, longitudinal, to evaluate the therapuetic efficacy to dislipydemias in mexican adult population.
- Trial name
- NCT03696940
- Testing
- L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg, Atorvastatin 10mg
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Laboratorios Grossman, S.A.
Primary Hypercholesterolemia
A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)
This is a study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe when added to ongoing therapy with an 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) in participants…
- Trial name
- NCT03882905
- Testing
- Ezetimibe, Simivastatin, Statin
- Volunteers
- 769 people
- Sponsor
- Organon and Co
Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery
This is a multi-center, randomized study of sitaxsentan administered intravenously to subjects who are undergoing elective CABG, cardiac valve replacement, or combined CABG and cardiac valve replacement procedures that require…
- Trial name
- FCAD02 (NCT00838383)
- Testing
- sitaxsentan (Thelin)
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Pfizer
Cardiovascular Risk Factor, Cardiovascular Diseases
Utility of the SomaLogic Cardiovascular Disease (CVD) Secondary Risk Panel for Cardiovascular Risk
This is a prospective pilot study of participants who have stable coronary heart disease (CHD). Participants undergo risk stratification using the SomaLogic Cardiovascular Disease (CVD) Risk Panel blood test at baseline and again…
- Trial name
- NCT03599531
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- SomaLogic, Inc.
Blood Pressure
Effect of a Probiotic-based Product on Blood Pressure
The aim of the present study was to examine the efficacy of a probiotic-based product on either reducing hypertension or preventing a high normal blood pressure from reaching hypertensive levels.
- Trial name
- NCT01989702
- Testing
- Fermented blueberry drink, Sachets with probiotic bacterial powder
- Where
- Sweden
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Probi AB
Atrial Fibrillation
Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
Primary Objective: Demonstrate the efficacy of Dronedarone in preventing major cardiovascular events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or unplanned cardiovascular hospitalization…
- Trial name
- PALLAS (NCT01151137)
- Testing
- Dronedarone
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 3,236 people
- Sponsor
- Sanofi
Atherosclerotic Cardiovascular Disease
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Italy)
This study will evaluate cardiovascular outcomes among individuals with clinically established atherosclerotic cardiovascular disease (ASCVD) who have not previously experienced a myocardial infarction (MI) or ischemic stroke.
- Trial name
- NCT07906132
- Where
- Italy
- Volunteers
- 93,000 people
- Sponsor
- Sanofi
Glycemia, Hypertension
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care…
- Conditions
- Glycemia, Hypertension, Hyperlipidemia
- Trial name
- PATROL (NCT00891124)
- Where
- 7 sites in South Korea
- Volunteers
- 4,045 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Cardiovascular Diseases
Clinical Study for the Investigation and Validation of a Therapy Procedure for the Adjustment of Risk Factors in Patients With Coronary Heart Disease by Means of Digital Therapy Control
This study will test a controlled investigation of the efficacy and effectiveness of iATROS digital therapy management for risk factor adjustment in patients with coronary heart disease (CHD).
- Conditions
- Coronary Artery Disease, Cardiovascular Diseases, Coronary Heart Disease, Ischemic Heart Disease
- Trial name
- ERKHA (NCT06091774)
- Testing
- CHD therapy through iATROS medical device
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- iATROS GmbH
Obesity, Intra-Abdominal Fat
Effect of a Probiotic on Visceral Fat Accumulation
The study's main objective is to investigate if an extract containing the probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) has a positive effect on the accumulation of abdominal visceral fat in people with…
- Conditions
- Obesity, Intra-Abdominal Fat, Subcutaneous Fat, Abdominal
- Trial name
- BIFFAT (NCT02921217)
- Testing
- Active Probiotic, Inactivated probiotic, Control
- Where
- Spain
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Biopolis S.L.
Chronic Kidney Disease (CKD)
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
The purpose of this study is to evaluate which clinical and laboratory factors are associated with major adverse cardiovascular event (MACE) in chronic kidney disease (CKD) patients on dialysis.
- Trial name
- NCT04042350
- Testing
- Non-interventional
- Where
- Sweden
- Volunteers
- 2,773 people
- Sponsor
- Astellas Pharma Europe Ltd.